Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

The 21-year-old woman was in agony. For five years, her own body had waged a violent war against her colon. She had ...

Bristol Myers Squibb BMY recently obtained FDA approval for the label expansion of Breyanzi (lisocabtagene maraleucel) for ...

Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results.

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...

Partnership enables ImmunoACT to offer eligible patients a bridge financing plan and value-based offering to access its NexCAR19 (TM) CAR-T therapy for leukaemia and lymphoma.

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or ...

Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...

Lisocabtagene maraleucel (liso-cel) is now the only CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for MZL. The approval marks liso-cel’s fifth indication, the most of any ...